J. Craig Venter, Scientist Who Raced to Decode the Human Genome, Dies at 79

J. Craig Venter, the scientist and entrepreneur whose private-sector drive to sequence the human genome reshaped modern biology, died Wednesday in San Diego at age 79. The J. Craig Venter Institute confirmed he died following a brief hospitalization for unexpected side effects arising from treatment for recently diagnosed cancer.

The Details

Venter died April 29, 2026, according to a press release from the J. Craig Venter Institute, the nonprofit research organization he founded. The New York Times corroborated the death, reporting that Venter had died Wednesday in San Diego. He was 79.

The cause, according to JCVI, was unexpected complications that arose during treatment for a cancer diagnosis that had only recently been made. The institute did not identify the type of cancer or specify the treatment involved.

Venter's most celebrated chapter came in the late 1990s, when he led Celera Genomics in a high-profile race against the publicly funded Human Genome Project to sequence the full human genome. According to a 2011 profile in Mayo Clinic Proceedings, Venter — alongside Francis Collins, who directed the National Institutes of Health consortium — was a primary force behind the project. In June 2000, the two men stood together at the White House and jointly announced a rough draft of the human genome, a milestone that altered the trajectory of medicine and biological research.

Before Celera, Venter had already changed how scientists approached gene discovery. According to Britannica, he pioneered the use of expressed sequence tags — short stretches of DNA that serve as markers for active genes — a technique that dramatically accelerated the process of identifying genes across the genome.

Celera's approach, called whole-genome shotgun sequencing, was faster and more controversial than the publicly funded method. Venter's willingness to commercialize what many researchers considered a shared scientific heritage drew sustained criticism even as it accelerated the field. The public and private projects published their findings simultaneously in 2001.

After Celera, Venter turned toward synthetic biology. JCVI credited him in its death announcement with launching the field and leading the work that produced the first self-replicating bacterial cell controlled entirely by a chemically synthesized genome — an achievement reached in 2010. SynBioBeta, which covers the synthetic biology industry, called that milestone foundational to the field's growth and described Venter as one of synthetic biology's founding giants.

"Craig believed that science moves forward when people are willing to think differently, move decisively, and build what doesn't yet exist," said Anders Dale, president of JCVI, in the institute's announcement.

Context

Venter was born October 14, 1946, in Salt Lake City, Utah, according to Britannica. He served in the U.S. Naval Medical Corps during the Vietnam War before returning to earn degrees at UC San Diego, where he later built the academic foundation for his research career.

Over the following decades, Venter established or led a series of organizations that tracked the frontiers of genomic and synthetic biology research. Britannica and SynBioBeta identify those institutions as the Institute for Genomic Research (TIGR), Celera Genomics, the J. Craig Venter Institute, Synthetic Genomics, Human Longevity, and most recently Diploid Genomics.

Each organization reflected a successive ambition: first to map genes, then to read entire genomes, then to synthesize new ones, and finally to apply genomic data at clinical scale. The through-line across all of them was Venter's conviction that biology could be engineered, not merely observed.

Venter's legacy in synthetic biology — the discipline that treats genetic sequences as programmable code — is particularly durable. The 2010 synthetic-cell work, which JCVI credited to Venter's leadership, demonstrated for the first time that a cell could be directed entirely by an artificially written genome. That proof-of-concept has since informed a generation of research into programmable organisms, minimal genomes, and cell-based therapeutics.

What's Next

JCVI did not announce a successor to Venter in its death statement. Anders Dale, named as JCVI's president in the announcement, is expected to lead the institute's operations going forward, though the institute made no formal transition announcement.

Venter had been active in his most recent venture, Diploid Genomics, at the time of his death. The institute's statement did not address the operational future of Diploid Genomics following his death.

Venter's passing removes one of the field's most prominent advocates for rapid, commercially driven science. As JCVI noted in its statement, his approach — thinking differently, moving decisively, building what doesn't exist — defined the culture he built across multiple institutions over more than three decades.